abstract |
The invention relates to the use of histamine to induce the polarisation of dendritic cells and, more specifically, to induce the polarisation of dendritic cells into type 2 dendritic cells, which are used, in particular, for the therapeutic and prophylactic treatment of pathologies associated with an excessive Th1 response. |